BBLG

Bone Biologics Corp

NASDAQ: BBLG · HEALTHCARE · BIOTECHNOLOGY

$1.31

-0.10% today

Updated 2026-06-05

Market cap

$2.30M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.16

Dividend yield

—

52W range

$1 – $7

Volume

0.0M

Market cap

$2.30M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.16

Dividend yield

—

52W range

$1 – $7

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$22.20

+1594.66%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-804282.00

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-1.48M	$-8.95M	$-4.11M	$-3.11M	$-765988.00
EPS	—	—	—	—	$-1.16
Free cash flow	$-3.57M	$-9.56M	$-4.12M	$-2.69M	$-804282.00
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
BBLG	$2.30M	26	4.3	3.0	5.0	6.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Bone Biologics Corp trades at $1.31. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score.

Frequently asked questions

What is Bone Biologics Corp's stock price?

Bone Biologics Corp (BBLG) trades at $1.31.

Is Bone Biologics Corp overvalued?

Bone Biologics Corp carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Bone Biologics Corp (BBLG)?

The 12-month analyst consensus target is $22.20, about 1594.7% above the current $1.31. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-61.20%

Beta0.53

50D MA$1.27

200D MA$1.68

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

BBLG vs LLY →BBLG vs JNJ →BBLG vs ABBV →Stock screener →